|
May 27
|
Press Release: Sanofi completes acquisition of DR-0201
|
|
May 23
|
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
|
|
May 22
|
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
|
|
May 22
|
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
|
|
May 22
|
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
|
|
May 22
|
European Equities Close Lower in Thursday Trading; Eurozone Business Activity Swings to Contraction
|
|
May 22
|
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
|
|
May 22
|
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
|
|
May 22
|
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
|
|
May 22
|
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
|
|
May 22
|
Sanofi gains experimental Alzheimer’s drug through Vigil buyout
|
|
May 22
|
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
|
|
May 22
|
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
|
|
May 22
|
Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play
|
|
May 21
|
Sanofi to Buy Vigil Neuroscience for About $470 Million
|
|
May 21
|
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
|
|
May 21
|
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
|
|
May 21
|
Viz.ai, Sanofi and Regeneron to link for COPD management
|
|
May 20
|
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management
|
|
May 20
|
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
|